Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof of Mechanism Study of GSK239512 for Remyelination in Relapsing Remitting Multiple Sclerosis
2012-003627-38Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing GSK239512 with Placebo (2 arms). Started Sep 2012; status: completed.
02
Drugs
gsk239512
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-003627-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003627-38.